Patient must give explicit consent
A lot of scientific research is carried out at the Radboudumc. This is necessary to develop new and improved treatments for our patients. With patients' consent, we can use their medical data, leftover biomaterial (such as blood, urine or tissue) and images for scientific research and education.
A conscious choice
In the past, obtaining consent from patients was arranged via the opt-out method. This meant that medical data and remaining biomaterial and images were accessible to researchers unless the patient explicitly objected. However, many patients were not aware that their medical data and material could be used for scientific research. To improve the consent procedure, the NFU decided to run a trial with the opt-in method, in which the Radboudumc participates. With this method, the patient is explicitly asked for permission in advance. This consent procedure will apply from January 2020 for all new patients who register as a patient at Radboudumc for the first time. Until further notice, the opt-in method will be used.
How do we request permission now?
New eligible patients will be asked for their consent when registering at the central registration desk. The answer is immediately registered in Epic. Sometimes a patient is not approached at the central registration desk. In this case, the patient receives a request via mijnRadboud or a letter at home. Patients can always adjust the choice made via mijnRadboud or via the reception desk staff.
Will this affect my research?
When using medical data from patient records or leftover biomaterial and images, you should always check the patient's current consent status in Epic. If a patient has objected or has not responded, you will not be able to use the patient's data and material. A patient can change their status at any time, so it is important to regularly check the consent status in the system.
You will find more information for patients (in Dutch) about the use of medical data and leftover biomaterial at the Radboudumc here .
Contact person: Jennifer Lutomski, Radboud Biobank.
Related news items
The future of laboratory animal research More attention to living conditions of laboratory animals16 May 2022
On May 9, a meeting took place at the Radboudumc as a result of the launch of the Dutch Transparency Agreement on Animal Testing. The Radboudumc is one of the twenty signatories and has thus committed itself to openly and transparently communicate its vision and policy with regard to animal testing.read more
Arnhem Nijmegen: top region in Health, High-Tech and Energy10 February 2022
Projects in the Arnhem Nijmegen region can expect millions of extra euros in the coming years. This will be used for, amongst other things, the circular economy and pioneering applications in the fields of Health, High-tech and Energy.read more
Micro-Cosmos helps patient unwind during hospitalization10 February 2022
Nijmegen-based Micro-Cosmos is a start-up that makes retractable hoods to speed up the recovery of hospitalized patients.read more
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more